{"entity":{"id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","aka":["Duravelo-2"],"tldr":"A phase 2 trial of Zelenectide pevedotin, Pembrolizumab, Carboplatin, Cisplatin, Gemcitabine and Gemcitabine + cisplatin in bladder & urothelial cancer, run by BicycleTx Limited, active and no longer recruiting.","summary":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) is a phase 2 interventional study registered as NCT06225596 by BicycleTx Limited, with 375 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-03. Interventions recorded: Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin and Avelumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06225596","url":"https://clinicaltrials.gov/study/NCT06225596"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["peptide-drug-conjugate"],"targets":[],"drugs":["zelenectide-pevedotin","pembrolizumab","carboplatin","cisplatin","gemcitabine","gemcitabine-cisplatin"],"companies":["bicycle-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06225596","phase":"2","setting":"A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","sponsor":"BicycleTx Limited","started":"2024-01-24","startedType":"actual","enrolled":375,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06225596/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/"}],"company":[{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/"}]}}